Kiniksa Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kiniksa Pharmaceuticals (KNSA).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$82Upside to Avg. PT+8.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 30, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$75→$90
Jul 29, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$72→$107
Jul 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$64→$98
Jul 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$72→$99
Jul 29, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$60→$100
Jul 23, 2026	Goldman Sachs	Paul Choi	PT Raise	Buy	$60→$75
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$57→$74
Jun 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$59→$72
Apr 29, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$64
Apr 29, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$60
Apr 29, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$58→$59
Apr 29, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$53→$57
Apr 28, 2026	Jefferies	Roger Song	PT Raise	Buy	$58→$71
Apr 16, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$53→$58
Feb 25, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$50→$53
Feb 25, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$50→$53
Feb 19, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$62
Jan 13, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$48→$50
Oct 29, 2025	Goldman Sachs	Paul Choi	PT Raise	Buy	$45→$55
Oct 17, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$45→$50

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $64 to $98.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.

Benzinga Newsdesk

Kiniksa Pharmaceuticals International PLC

뉴스

파트너 / 기고자

벤징가 글로벌

Kiniksa Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

People Also Watch

People Also Watch

Kiniksa Pharmaceuticals International PLC

뉴스

파트너 / 기고자

벤징가 글로벌

Kiniksa Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PROCanaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

PROWedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

PROCitigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

People Also Watch

People Also Watch

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75